

Hanneke W M Van Laarhoven

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7791023/publications.pdf>

Version: 2024-02-01

356
papers

12,828
citations

34105

52
h-index

38395

95
g-index

357
all docs

357
docs citations

357
times ranked

17340
citing authors

#	ARTICLE	IF	CITATIONS
1	Response shift after coronary revascularization. <i>Quality of Life Research</i> , 2022, 31, 437-450.	3.1	8
2	Narrative recognition and identification: a qualitative pilot study into reading literary texts with advanced cancer patients. <i>Journal of Cancer Survivorship</i> , 2022, 16, 531-541.	2.9	4
3	Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit. <i>Gastric Cancer</i> , 2022, 25, 22-32.	5.3	15
4	Spiritual Well-Being and Associated Factors in Dutch Patients With Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2022, 63, 404-414.	1.2	5
5	Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial. <i>Gastric Cancer</i> , 2022, 25, 401-410.	5.3	12
6	Muslim doctors and decision making in palliative care: a discourse analysis. <i>Mortality</i> , 2022, 27, 289-306.	0.5	2
7	Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181. <i>Journal of Clinical Oncology</i> , 2022, 40, 382-391.	1.6	13
8	Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. <i>Journal of Pathology</i> , 2022, 256, 282-296.	4.5	11
9	Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment. <i>Supportive Care in Cancer</i> , 2022, 30, 2407-2415.	2.2	2
10	Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population-based study. <i>Cancer Science</i> , 2022, , .	3.9	7
11	This is what life with cancer looks like: exploring experiences of adolescent and young adults with cancer using two visual approaches. <i>Supportive Care in Cancer</i> , 2022, 30, 3353-3361.	2.2	4
12	The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periapillary Diseases, a Novel Approach. <i>Cancers</i> , 2022, 14, 344.	3.7	10
13	Age-specific incidence, treatment, and survival trends in esophageal cancer: a Dutch population-based cohort study. <i>Acta Oncologica</i> , 2022, 61, 545-552.	1.8	7
14	Beyond median overall survival: Estimating multiple survival scenarios in patients with metastatic esophagogastric cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 261-261.	1.6	1
15	Improving survival prediction of patients treated with external beam radiotherapy for dysphagia in esophageal cancer using prediction models.. <i>Journal of Clinical Oncology</i> , 2022, 40, 358-358.	1.6	0
16	Survival expressed in best-case, typical and worst-case scenarios for patients with nonmetastatic esophagogastric cancer: A population-based study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 259-259.	1.6	0
17	Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials. <i>Gastric Cancer</i> , 2022, 25, 640-651.	5.3	10
18	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. <i>European Journal of Cancer</i> , 2022, 164, 18-29.	2.8	27

#	ARTICLE	IF	CITATIONS
19	A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210754.	3.2	4
20	A population-based study in synchronous <i>versus</i> metachronous metastatic esophagogastric adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210855.	3.2	2
21	Treatment decision-making during outpatient clinic visit of patients with esophagogastric cancer. The perspectives of clinicians and patients, a mixed method, multiple case study. <i>Cancer Medicine</i> , 2022, , .	2.8	1
22	Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study. <i>Frontiers in Oncology</i> , 2022, 12, 839779.	2.8	9
23	Quality of life and quality of care as experienced by patients with advanced cancer and their relatives: A multicentre observational cohort study (eQuiPe). <i>European Journal of Cancer</i> , 2022, 165, 125-135.	2.8	22
24	Co-creative art processes with patients: A theoretical framework and qualitative study among artists. <i>PLoS ONE</i> , 2022, 17, e0266401.	2.5	2
25	Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2022, 150, 1654-1663.	5.1	11
26	The fear of cancer recurrence and progression in patients with pancreatic cancer. <i>Supportive Care in Cancer</i> , 2022, 30, 4879-4887.	2.2	4
27	Improving survival prediction of oesophageal cancer patients treated with external beam radiotherapy for dysphagia. <i>Acta Oncologica</i> , 2022, 61, 849-855.	1.8	0
28	Time to access to novel anticancer drugs in Europe, a case study in seven European countries.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1586-1586.	1.6	2
29	Physical activity levels in patients with melanoma during treatment with immune checkpoint inhibitors: Fitbit results from the CAMP-IT trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13610-e13610.	1.6	0
30	Anti-PD1, capecitabine, and oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCIOUS-dMMR): A proof-of-principle study (AuspiCIOUS).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4163-TPS4163.	1.6	0
31	Turkish imams and their role in decision-making in palliative care: A Directed Content and Narrative analysis. <i>Palliative Medicine</i> , 2022, 36, 1006-1017.	3.1	3
32	Timing of onset of systemic treatment in asymptomatic patients with metastatic pancreatic cancer: An international expert survey and case-vignette study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16256-e16256.	1.6	1
33	Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer. <i>Cancers</i> , 2022, 14, 2963.	3.7	0
34	Deep learning DCE-MRI parameter estimation: Application in pancreatic cancer. <i>Medical Image Analysis</i> , 2022, 80, 102512.	11.6	17
35	A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT). <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211091.	3.2	3
36	SOURCE beyond first-line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first-line palliative systemic therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4037-4037.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Delayed versus immediate start of chemotherapy in asymptomatic patients with metastatic cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2022, 40, 12126-12126.	1.6	1
38	Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: A randomized phase II proof-of-concept study (NCT04554771).. Journal of Clinical Oncology, 2022, 40, TPS4166-TPS4166.	1.6	0
39	The role of hospital nurses in shared decisionâ€making about lifeâ€prolonging treatment: A qualitative interview study. Journal of Advanced Nursing, 2021, 77, 296-307.	3.3	30
40	Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study. Acta OncolÃ³gica, 2021, 60, 497-504.	1.8	23
41	Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). Clinical Cancer Research, 2021, 27, 3351-3359.	7.0	143
42	A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers, 2021, 13, 839.	3.7	2
43	Cachexia and Dietetic Interventions in Patients With Esophagogastric Cancer: A Multicenter Cohort Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 144-152.	4.9	15
44	Perceived Care and Well-being of Patients With Cancer and Matched Norm Participants in the COVID-19 Crisis. JAMA Oncology, 2021, 7, 279.	7.1	56
45	Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Annals of Oncology, 2021, 32, 360-367.	1.2	40
46	Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study. Journal of the National Cancer Institute, 2021, 113, 1551-1560.	6.3	23
47	Perceptions of involvement in advance care planning and emotional functioning in patients with advanced cancer. Journal of Cancer Survivorship, 2021, 15, 380-385.	2.9	4
48	Changes in hospital variation in the probability of receiving treatment with curative intent for esophageal and gastric cancer. Cancer Epidemiology, 2021, 71, 101897.	1.9	5
49	Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study. Clinical Cancer Research, 2021, 27, 3784-3792.	7.0	30
50	Comprehensive ambulatory monitoring during immunotherapy in patients with advanced melanoma: A prospective trial (CAMP-IT).. Journal of Clinical Oncology, 2021, 39, TPS1589-TPS1589.	1.6	0
51	Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, e16239-e16239.	1.6	2
52	Circulating tumor DNA (ctDNA) analysis by low-coverage whole genome sequencing (lcWGS) of resectable esophageal adenocarcinoma (rEAC) patients.. Journal of Clinical Oncology, 2021, 39, 4033-4033.	1.6	0
53	Pre-Operative Decitabine in Colon Cancer Patients: Analyses on WNT Target Methylation and Expression. Cancers, 2021, 13, 2357.	3.7	2
54	Potential mechanisms of the fatigueâ€reducing effect of cognitiveâ€behavioral therapy in cancer survivors: Three randomized controlled trials. Psycho-Oncology, 2021, 30, 1476-1484.	2.3	11

#	ARTICLE	IF	CITATIONS
55	Digital Self-Management Support Tools in the Care Plan of Patients With Cancer: Review of Randomized Controlled Trials. <i>Journal of Medical Internet Research</i> , 2021, 23, e20861.	4.3	18
56	The association between wearable activity monitor metrics and performance status in oncology: a systematic review. <i>Supportive Care in Cancer</i> , 2021, 29, 7085-7099.	2.2	7
57	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1995-2004.	1.6	291
58	Improved unsupervised physics-informed deep learning for intravoxel incoherent motion modeling and evaluation in pancreatic cancer patients. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 2250-2265.	3.0	41
59	Repeated use of rich pictures to explore changes in subjective experiences over time of patients with advanced cancer. <i>Cancer Reports</i> , 2021, , e1428.	1.4	2
60	Validation of the FACITâ€12 in a Dutch cohort of patients with advanced cancer. <i>Psycho-Oncology</i> , 2021, 30, 1930-1938.	2.3	6
61	A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1742-1749.	1.0	5
62	Bereaved relativesâ€™ quality of life before and during the COVID-19 pandemic: Results of the prospective, multicenter, observational eQuiPe study. <i>Palliative Medicine</i> , 2021, 35, 1502-1507.	3.1	6
63	Informing Patients With Esophagogastric Cancer About Treatment Outcomes by Using a Web-Based Tool and Training: Development and Evaluation Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e27824.	4.3	6
64	Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. <i>Frontiers in Genetics</i> , 2021, 12, 693933.	2.3	10
65	Presentation, Treatment, and Prognosis of Esophageal Carcinoma in A Nationwide Comparison of Sweden and the Netherlands. <i>Annals of Surgery</i> , 2021, Publish Ahead of Print, 743-750.	4.2	9
66	Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4869.	3.7	7
67	Experienced quality of care and emotional functioning of patients with advanced cancer and their relatives: Results of a multicenter observational cohort study (eQuiPe).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3-3.	1.6	6
68	Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma. <i>Oncolmmunology</i> , 2021, 10, 1954807.	4.6	17
69	SOURCE: Prediction Models for Overall Survival in Patients With Metastatic and Potentially Curable Esophageal and Gastric Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 403-410.	4.9	7
70	First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , 1-8.	4.9	6
71	Personalized versus standard cognitive behavioral therapy for fear of cancer recurrence, depressive symptoms or cancer-related fatigue in cancer survivors: study protocol of a randomized controlled trial (MATCH-study). <i>Trials</i> , 2021, 22, 696.	1.6	1
72	Bayesian log-normal deconvolution for enhanced in silico microdissection of bulk gene expression data. <i>Nature Communications</i> , 2021, 12, 6106.	12.8	7

#	ARTICLE	IF	CITATIONS
73	Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. <i>Frontiers in Oncology</i> , 2021, 11, 771312.	2.8	8
74	Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 12-29.	6.3	25
75	Spiritual care by nurses in curative oncology: a mixedâ€method study on patientsâ€™ perspectives and experiences. <i>Scandinavian Journal of Caring Sciences</i> , 2020, 34, 96-107.	2.1	12
76	Muscle Strength Is Associated With Muscle Mass in Patients With Esophageal Cancer Awaiting Surgery. <i>Journal of Geriatric Physical Therapy</i> , 2020, 43, 82-88.	1.1	3
77	Distribution of lymph node metastases in esophageal adenocarcinoma after neoadjuvant chemoradiation therapy: a prospective study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 4347-4357.	2.4	16
78	Heterogeneity of firstâ€line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A realâ€world evidence study. <i>International Journal of Cancer</i> , 2020, 146, 1889-1901.	5.1	29
79	Rapid stromal remodeling by shortâ€term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma. <i>Molecular Oncology</i> , 2020, 14, 704-720.	4.6	7
80	Feasibility of extended chemoradiotherapy plus surgery for patients with cT4b esophageal carcinoma. <i>European Journal of Surgical Oncology</i> , 2020, 46, 626-631.	1.0	9
81	From presentation to paper: Gender disparities in oncological research. <i>International Journal of Cancer</i> , 2020, 146, 3011-3021.	5.1	9
82	The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. <i>Hpb</i> , 2020, 22, 233-240.	0.3	66
83	Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2020, 125, 83-93.	2.8	98
84	Gastro-oesophageal junction: to FLOT or to CROSS?. <i>Acta OncolÃ³gica</i> , 2020, 59, 233-236.	1.8	7
85	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2â€Positive Esophageal Adenocarcinoma: TRAP Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 462-471.	1.6	44
86	Effect of a Skills Training for Oncologists and a Patient Communication Aid on Shared Decision Making About Palliative Systemic Treatment: A Randomized Clinical Trial. <i>Oncologist</i> , 2020, 25, e578-e588.	3.7	37
87	Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patientsâ€™ perspective. <i>European Journal of Cancer</i> , 2020, 136, 132-139.	2.8	120
88	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. <i>European Journal of Cancer</i> , 2020, 141, 171-184.	2.8	65
89	Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial. <i>Cancer Medicine</i> , 2020, 9, 6609-6616.	2.8	8
90	Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab. <i>MAbs</i> , 2020, 12, 1795492.	5.2	11

#	ARTICLE	IF	CITATIONS
91	Health-related quality of life in curatively-treated patients with esophageal or gastric cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 154, 103069.	4.4	32
92	Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: A multicenter cohort study. <i>Cancer Medicine</i> , 2020, 9, 9385-9395.	2.8	12
93	Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study. <i>European Journal of Cancer</i> , 2020, 139, 107-118.	2.8	10
94	Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. <i>JAMA Oncology</i> , 2020, 6, 1733.	7.1	85
95	Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma. <i>Biomedicines</i> , 2020, 8, 444.	3.2	9
96	Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures. <i>Radiotherapy and Oncology</i> , 2020, 153, 97-105.	0.6	19
97	Is chemotherapy for advanced or metastatic oesophageal squamous cell carcinoma no longer needed?. <i>Lancet Oncology</i> , The, 2020, 21, 743-745.	10.7	6
98	Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188386.	7.4	67
99	Older versus younger adults with gastric cancer receiving perioperative treatment: Results from the CRITICS trial. <i>European Journal of Cancer</i> , 2020, 130, 146-154.	2.8	17
100	Gender differences in quality of life in coronary artery disease patients with comorbidities undergoing coronary revascularization. <i>PLoS ONE</i> , 2020, 15, e0234543.	2.5	12
101	Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 756-767.	7.3	34
102	Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. <i>Acta Oncologica</i> , 2020, 59, 705-712.	1.8	9
103	Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. <i>Oncologist</i> , 2020, 25, e634-e643.	3.7	33
104	Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. <i>Annals of Surgical Oncology</i> , 2020, 27, 2516-2524.	1.5	36
105	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. <i>Nature Communications</i> , 2020, 11, 525.	12.8	158
106	Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. <i>Gastric Cancer</i> , 2020, 23, 579-590.	5.3	16
107	The Effect of Prognostic Communication on Patient Outcomes in Palliative Cancer Care: a Systematic Review. <i>Current Treatment Options in Oncology</i> , 2020, 21, 40.	3.0	35
108	MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. <i>Cancer Treatment Reviews</i> , 2020, 86, 102024.	7.7	90

#	ARTICLE	IF	CITATIONS
109	A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. <i>Acta Oncologica</i> , 2020, 59, 895-903.	1.8	10
110	High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. <i>EMBO Reports</i> , 2020, 21, e48780.	4.5	29
111	Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience. <i>Molecular Oncology</i> , 2020, 14, 2176-2189.	4.6	23
112	External Validation of the Dutch SOURCE Survival Prediction Model in Belgian Metastatic Oesophageal and Gastric Cancer Patients. <i>Cancers</i> , 2020, 12, 834.	3.7	6
113	Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. <i>JCI Insight</i> , 2020, 5, .	5.0	36
114	Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer: A Multicenter Cohort Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1354-1363.	4.9	11
115	Randomized clinical trial on the effect of a supervised exercise program on quality of life, fatigue, and fitness following esophageal cancer treatment (PERFECT study).. <i>Journal of Clinical Oncology</i> , 2020, 38, 12055-12055.	1.6	1
116	A population-based study on gender differences in tumor and treatment characteristics and survival of curable gastroesophageal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4550-4550.	1.6	1
117	Ecological momentary assessment versus retrospective assessment for measuring change in health-related quality of life following cardiac intervention. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 98.	1.9	5
118	Accuracy of a single measurement site for self-monitoring of patients with breast cancer at risk for lymphedema. <i>Physiotherapy Theory and Practice</i> , 2019, 35, 1322-1327.	1.3	4
119	COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 684.	2.8	10
120	Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin. <i>Cancers</i> , 2019, 11, 871.	3.7	0
121	Vlogging at the end of life. <i>Lancet Oncology</i> , The, 2019, 20, 911-912.	10.7	1
122	Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study. <i>BMC Cancer</i> , 2019, 19, 662.	2.6	62
123	Living with advanced cancer: Rich Pictures as a means for health care providers to explore the experiences of advanced cancer patients. <i>Cancer Medicine</i> , 2019, 8, 4957-4966.	2.8	10
124	Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research</i> , 2019, 21, 97.	5.0	6
125	The Use of (Network) Meta-Analysis in Clinical Oncology. <i>Frontiers in Oncology</i> , 2019, 9, 822.	2.8	38
126	Influence of response shift and disposition on patient-reported outcomes may lead to suboptimal medical decisions: a medical ethics perspective. <i>BMC Medical Ethics</i> , 2019, 20, 61.	2.4	10

#	ARTICLE	IF	CITATIONS
127	Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy. <i>Nutrition and Cancer</i> , 2019, 71, 756-766.	2.0	8
128	Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 199-206.	7.3	86
129	Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2237-2242.	7.1	128
130	Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations. <i>British Journal of Cancer</i> , 2019, 121, 34-36.	6.4	16
131	Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984123.	3.2	35
132	Postoperative surveillance of pancreatic cancer patients. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1770-1777.	1.0	32
133	Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study). <i>Cancers</i> , 2019, 11, 827.	3.7	6
134	Contradiction between amideâ€CEST signal and pH in breast cancer explained with metabolic MRI. <i>NMR in Biomedicine</i> , 2019, 32, e4110.	2.8	20
135	Chemoradiation induces epithelialâ€toâ€mesenchymal transition in esophageal adenocarcinoma. <i>International Journal of Cancer</i> , 2019, 145, 2792-2803.	5.1	23
136	Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 530.	3.7	17
137	TOXview: a novel graphical presentation of cancer treatment toxicity profiles. <i>Acta OncolÃ³gica</i> , 2019, 58, 1138-1148.	1.8	9
138	Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). <i>BMC Cancer</i> , 2019, 19, 390.	2.6	83
139	Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 588.	3.7	42
140	Principal component analysis for fast and model-free denoising of multi b-value diffusion-weighted MR images. <i>Physics in Medicine and Biology</i> , 2019, 64, 105015.	3.0	22
141	Early detection of changes in phospholipid metabolism during neoadjuvant chemotherapy in breast cancer patients using phosphorus magnetic resonance spectroscopy at 7T. <i>NMR in Biomedicine</i> , 2019, 32, e4086.	2.8	20
142	Poor compliance with perioperative chemotherapy for resectable gastric cancer and its impact on survival. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1926-1933.	1.0	11
143	Cardiac molecular pathways influenced by doxorubicin treatment in mice. <i>Scientific Reports</i> , 2019, 9, 2514.	3.3	22
144	The dynamics in health-related quality of life of patients with stable coronary artery disease were revealed: a network analysis. <i>Journal of Clinical Epidemiology</i> , 2019, 107, 116-123.	5.0	11

#	ARTICLE	IF	CITATIONS
145	SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. <i>Cancers</i> , 2019, 11, 187.	3.7	20
146	Reconstructing Disruptive Life Events Using the RE-LIFE Questionnaire: Further Validation of the "Narrative Meaning Making of Life Events" Model Using Multiple Mediation Analysis. <i>Journal of Empirical Theology</i> , 2019, 32, 251-280.	0.8	1
147	Training for Medical Oncologists on Shared Decision-Making About Palliative Chemotherapy: A Randomized Controlled Trial. <i>Oncologist</i> , 2019, 24, 259-265.	3.7	36
148	Cutaneous Toxicity After Chemoradiotherapy and PD-L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye. <i>Oncologist</i> , 2019, 24, e149-e153.	3.7	5
149	Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage III breast cancer receiving chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 475-481.	2.5	26
150	Levels of choline-containing compounds in normal liver and liver metastases of colorectal cancer as recorded by ¹ H MRS. <i>NMR in Biomedicine</i> , 2019, 32, e4035.	2.8	5
151	Promoting shared decision making in advanced cancer: Development and piloting of a patient communication aid. <i>Patient Education and Counseling</i> , 2019, 102, 916-923.	2.2	14
152	The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis. <i>Cancers</i> , 2019, 11, 80.	3.7	30
153	An assisted structured reflection on life events and life goals in advanced cancer patients: Outcomes of a randomized controlled trial (Life InSight Application (LISA) study). <i>Palliative Medicine</i> , 2019, 33, 221-231.	3.1	7
154	Relationship between physicians' death anxiety and medical communication and decision-making: A systematic review. <i>Patient Education and Counseling</i> , 2019, 102, 266-274.	2.2	42
155	Low reported taste function is associated with low preference for high protein products in advanced oesophagogastric cancer patients undergoing palliative chemotherapy. <i>Clinical Nutrition</i> , 2019, 38, 472-475.	5.0	7
156	A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 4045-4045.	1.6	20
157	Tailored Web-Based Information for Younger and Older Patients with Cancer: Randomized Controlled Trial of a Preparatory Educational Intervention on Patient Outcomes. <i>Journal of Medical Internet Research</i> , 2019, 21, e14407.	4.3	22
158	Trends in treatment and overall survival among patients with proximal esophageal cancer. <i>World Journal of Gastroenterology</i> , 2019, 25, 6835-6846.	3.3	13
159	From presentation to paper: Gender disparities in oncological research. <i>Journal of Clinical Oncology</i> , 2019, 37, 10523-10523.	1.6	0
160	Health-related quality of life (HRQoL) of pembrolizumab (pembro) versus physician choice single-agent paclitaxel, docetaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma (ACC) or squamous cell carcinoma (SCC) of the esophagus that has progressed after first-line standard therapy (KEYNOTE-181). <i>Journal of Clinical Oncology</i> , 2019, 37, 4048-4048.	1.6	0
161	Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2018, 26, 1383-1392.	2.2	8
162	Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. <i>Hpb</i> , 2018, 20, 605-611.	0.3	69

#	ARTICLE	IF	CITATIONS
163	Repeatability and correlations of dynamic contrast enhanced and T2* MRI in patients with advanced pancreatic ductal adenocarcinoma. <i>Magnetic Resonance Imaging</i> , 2018, 50, 1-9.	1.8	16
164	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , The, 2018, 19, e151-e160.	10.7	51
165	Are the effects of cognitive behavior therapy for severe fatigue in cancer survivors sustained up to 14 years after therapy?. <i>Journal of Cancer Survivorship</i> , 2018, 12, 519-527.	2.9	16
166	Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 616-628.	10.7	397
167	Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis. <i>International Journal of Cancer</i> , 2018, 143, 438-448.	5.1	22
168	Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review. <i>Gastric Cancer</i> , 2018, 21, 183-195.	5.3	15
169	Altered food preferences and chemosensory perception during chemotherapy in breast cancer patients: A longitudinal comparison with healthy controls. <i>Food Quality and Preference</i> , 2018, 63, 135-143.	4.6	26
170	The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. <i>International Journal of Hyperthermia</i> , 2018, 34, 969-979.	2.5	41
171	Hospital of Diagnosis Influences the Probability of Receiving Curative Treatment for Esophageal Cancer. <i>Annals of Surgery</i> , 2018, 267, 303-310.	4.2	25
172	Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 268-275.	1.6	91
173	Lymph node metastases near the celiac trunk should be considered separately from other nodal metastases in patients with cancer of the esophagus or gastroesophageal junction after neoadjuvant treatment and surgery. <i>Journal of Thoracic Disease</i> , 2018, 10, 1511-1521.	1.4	3
174	Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients. <i>PLoS ONE</i> , 2018, 13, e0207362.	2.5	31
175	Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 36-37, 45-52.	2.4	13
176	The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 36-37, 53-59.	2.4	12
177	Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2018, 103, 214-226.	2.8	28
178	Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. <i>Acta Oncologica</i> , 2018, 57, 1655-1662.	1.8	70
179	Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis. <i>Acta Oncologica</i> , 2018, 57, 1599-1604.	1.8	13
180	Who should provide care for patients receiving palliative chemotherapy? A qualitative study among Dutch general practitioners and oncologists. <i>Scandinavian Journal of Primary Health Care</i> , 2018, 36, 437-445.	1.5	4

#	ARTICLE	IF	CITATIONS
181	A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas. <i>Scientific Reports</i> , 2018, 8, 13281.	3.3	28
182	CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. <i>BMC Cancer</i> , 2018, 18, 877.	2.6	115
183	Interferon Gamma-Induced Protein (IP-10) as Potential Biomarker for Cancer-Related-Fatigue: Results from a 6-month Randomized Controlled Trial. <i>Cancer Investigation</i> , 2018, 36, 371-377.	1.3	3
184	Multidrug-resistant transporter expression does not always result in drug resistance. <i>Cancer Science</i> , 2018, 109, 3360-3362.	3.9	2
185	Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. <i>Lancet Oncology</i> , The, 2018, 19, 965-974.	10.7	211
186	Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands. <i>Acta Oncologica</i> , 2018, 57, 1185-1191.	1.8	15
187	Group medical consultations (GMCs) and tablet-based online support group sessions in the follow-up of breast cancer: A multicenter randomized controlled trial. <i>Breast</i> , 2018, 40, 181-188.	2.2	26
188	Comparison of six fit algorithms for the intra-voxel incoherent motion model of diffusion-weighted magnetic resonance imaging data of pancreatic cancer patients. <i>PLoS ONE</i> , 2018, 13, e0194590.	2.5	44
189	Evaluation of Six Diffusion-weighted MRI Models for Assessing Effects of Neoadjuvant Chemoradiation in Pancreatic Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1052-1062.	0.8	20
190	microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients. <i>Gastroenterology</i> , 2018, 155, 784-798.	1.3	70
191	IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity. <i>FASEB Journal</i> , 2018, 32, 6344-6352.	0.5	28
192	Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. <i>Acta Oncologica</i> , 2018, 57, 1475-1481.	1.8	58
193	Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012. <i>European Journal of Cancer</i> , 2018, 101, 77-86.	2.8	30
194	Amide chemical exchange saturation transfer at 7T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients. <i>Breast Cancer Research</i> , 2018, 20, 51.	5.0	36
195	Muslim physicians and palliative care: attitudes towards the use of palliative sedation. <i>Supportive Care in Cancer</i> , 2018, 26, 3701-3710.	2.2	11
196	Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study. <i>Biomedical Optics Express</i> , 2018, 9, 4196.	2.9	4
197	Assessment of Challenges Encountered by Dutch Oncologists When Patients Ask for Second Opinions. <i>JAMA Oncology</i> , 2018, 4, 1425.	7.1	5
198	The Role of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma and Preclinical Models to Study It. , 2018, , 735-748.		0

#	ARTICLE	IF	CITATIONS
199	Two novel registry-based prediction models for overall survival in patients with metastatic esophageal or gastric cancer.. Journal of Clinical Oncology, 2018, 36, 4021-4021.	1.6	3
200	Diversity of first-line palliative systemic treatments for esophagogastric cancer patients with synchronous metastases: A real world evidence study.. Journal of Clinical Oncology, 2018, 36, 4064-4064.	1.6	2
201	Circulating tumor DNA dynamics in resectable gastric cancer.. Journal of Clinical Oncology, 2018, 36, 4069-4069.	1.6	2
202	Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis. Oncotarget, 2018, 9, 28445-28455.	1.8	7
203	The dynamics of HER2 status in esophageal adenocarcinoma. Oncotarget, 2018, 9, 26787-26799.	1.8	17
204	Clinical and biological effects of demethylating agents on solid tumours – A systematic review. Cancer Treatment Reviews, 2017, 54, 10-23.	7.7	108
205	Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer. European Journal of Cancer, 2017, 78, 28-36.	2.8	24
206	The assessment of fatigue: Psychometric qualities and norms for the Checklist individual strength. Journal of Psychosomatic Research, 2017, 98, 40-46.	2.6	222
207	Spiritual care by nurses in curative cancer care: Protocol for a national, multicentre, mixed method study. Journal of Advanced Nursing, 2017, 73, 2201-2207.	3.3	13
208	Mindfulness-based stress reduction for breast cancer patients: a mixed method study on what patients experience as a suitable stage to participate. Supportive Care in Cancer, 2017, 25, 3067-3074.	2.2	22
209	Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. BMJ Open, 2017, 7, e014961.	1.9	69
210	Shared decision making about palliative chemotherapy: A qualitative observation of talk about patients' preferences. Palliative Medicine, 2017, 31, 625-633.	3.1	50
211	On the Receiving End of Autonomy and Law. Oncologist, 2017, 22, 1143-1145.	3.7	0
212	Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. Seminars in Cancer Biology, 2017, 44, 153-169.	9.6	68
213	Addition of MRI for CT-based pancreatic tumor delineation: a feasibility study. Acta Oncologica, 2017, 56, 923-930.	1.8	23
214	Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition. Gastroenterology, 2017, 153, 63-76.e14.	1.3	25
215	Molecular Tumor Boards: current practice and future needs. Annals of Oncology, 2017, 28, 3070-3075.	1.2	112
216	Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis. Scientific Reports, 2017, 7, 7142.	3.3	20

#	ARTICLE	IF	CITATIONS
217	The international phase 4 validation study of the EORTC QLQ-SWB32: A stand-alone measure of spiritual well-being for people receiving palliative care for cancer. <i>European Journal of Cancer Care</i> , 2017, 26, e12697.	1.5	24
218	Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 394-403.	7.4	45
219	Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel. <i>Drug Delivery</i> , 2017, 24, 1801-1810.	5.7	5
220	Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. <i>Cancer Medicine</i> , 2017, 6, 2840-2849.	2.8	41
221	Neoadjuvant chemotherapy in oesophageal adenocarcinoma. <i>Lancet Oncology</i> , The, 2017, 18, e639.	10.7	3
222	Weight change during chemotherapy in breast cancer patients: a meta-analysis. <i>BMC Cancer</i> , 2017, 17, 259.	2.6	91
223	Supraclavicular node disease is not an independent prognostic factor for survival of esophageal cancer patients treated with definitive chemoradiation. <i>Acta Oncologica</i> , 2017, 56, 33-38.	1.8	15
224	Images of God and attitudes towards death in relation to spiritual wellbeing: an exploratory side study of the EORTC QLQ-SWB32 validation study in palliative cancer patients. <i>BMC Palliative Care</i> , 2017, 16, 67.	1.8	14
225	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. <i>Oncotarget</i> , 2017, 8, 54434-54443.	1.8	13
226	ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3. <i>Oncotarget</i> , 2016, 7, 10243-10254.	1.8	27
227	Minimizing the Acquisition Time for Intravoxel Incoherent Motion Magnetic Resonance Imaging Acquisitions in the Liver and Pancreas. <i>Investigative Radiology</i> , 2016, 51, 211-220.	6.2	37
228	Revisiting the Potential of Alternating Repetition Time Balanced Steady-State Free Precession Imaging of the Abdomen at 3 T. <i>Investigative Radiology</i> , 2016, 51, 560-568.	6.2	4
229	Distribution of lymph node metastases on FDG-PET/CT in inoperable or unresectable oesophageal cancer patients and the impact on target volume definition in radiation therapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 520-527.	1.8	5
230	The effect of spiritual interventions addressing existential themes using a narrative approach on quality of life of cancer patients: a systematic review and meta-analysis. <i>Psycho-Oncology</i> , 2016, 25, 253-265.	2.3	67
231	Quantitative assessment of biliary stent artifacts on MR images: Potential implications for target delineation in radiotherapy. <i>Medical Physics</i> , 2016, 43, 5603-5615.	3.0	7
232	Oncologists' non-verbal behavior and analog patients' recall of information. <i>Acta Oncologica</i> , 2016, 55, 671-679.	1.8	19
233	Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysis. <i>Hpb</i> , 2016, 18, 559-566.	0.3	23
234	Reduced respiratory motion artifacts using structural similarity in fast 2D dynamic contrast enhanced MRI of liver lesions. <i>NMR in Biomedicine</i> , 2016, 29, 1526-1535.	2.8	1

#	ARTICLE	IF	CITATIONS
235	The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw166.	6.3	88
236	Chemoradiotherapy in tumours of the oesophagus and gastro-oesophageal junction. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 551-563.	2.4	12
237	Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 439-456.	5.9	39
238	Prognostic Significance of the Location of Lymph Node Metastases in Patients With Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction. <i>Annals of Surgery</i> , 2016, 264, 847-853.	4.2	37
239	Measurement Properties of Instruments for Measuring of Lymphedema: Systematic Review. <i>Physical Therapy</i> , 2016, 96, 1965-1981.	2.4	133
240	A qualitative study on mindfulness-based stress reduction for breast cancer patients: how women experience participating with fellow patients. <i>Supportive Care in Cancer</i> , 2016, 24, 1813-1820.	2.2	32
241	Insulin-like growth factor 1 receptor expression and IGF1R 3129G&T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research</i> , 2016, 18, 3.	5.0	30
242	The impact of chemosensory and food-related changes in patients with advanced oesophagogastric cancer treated with capecitabine and oxaliplatin: a qualitative study. <i>Supportive Care in Cancer</i> , 2016, 24, 3119-26.	2.2	23
243	S-1 with leucovorin and oxaliplatin for advanced gastric cancer. <i>Lancet Oncology</i> , The, 2016, 17, e41.	10.7	4
244	The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis. <i>Gastric Cancer</i> , 2016, 19, 696-712.	5.3	35
245	Cardiac monitoring during adjuvant trastuzumab therapy: Guideline adherence in clinical practice. <i>Acta Oncol&gica</i> , 2016, 55, 423-429.	1.8	12
246	Peer support and additional information in group medical consultations (GMCs) for <i>BRCA1/2</i> mutation carriers: A randomized controlled trial. <i>Acta Oncol&gica</i> , 2016, 55, 178-187.	1.8	5
247	Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215801.	0.5	3
248	Multicenter feasibility study of chemoradiation, trastuzumab and pertuzumab in resectable HER2+ esophageal carcinoma: The TRAP study.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4142-TPS4142.	1.6	0
249	CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study. <i>Chinese Clinical Oncology</i> , 2016, 5, 13.	1.2	4
250	Decision Making About Treatment for Advanced Cancer. <i>JAMA Oncology</i> , 2015, 1, 1169.	7.1	6
251	The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 501-507.	2.0	13
252	Breast Self-examination Education for BRCA Mutation Carriers by Clinical Nurse Specialists. <i>Clinical Nurse Specialist</i> , 2015, 29, E1-E7.	0.5	11

#	ARTICLE	IF	CITATIONS
253	Upregulation of IGF-1R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0117745.	2.5	32
254	Multimodality Imaging to Predict Response to Systemic Treatment in Patients with Advanced Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0120823.	2.5	33
255	¹⁸ F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making. <i>PLoS ONE</i> , 2015, 10, e0133690.	2.5	24
256	Feasibility and repeatability of PET with the hypoxia tracer [¹⁸ F]HX4 in oesophageal and pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2015, 116, 94-99.	0.6	44
257	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 821-827.	4.1	49
258	The Role of Central and Peripheral Muscle Fatigue in Postcancer Fatigue: A Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2015, 49, 173-182.	1.2	33
259	Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer. <i>Radiotherapy and Oncology</i> , 2015, 114, 91-95.	0.6	16
260	The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 97-114.	5.9	69
261	Group medical consultations in the follow-up of breast cancer: a randomized feasibility study. <i>Journal of Cancer Survivorship</i> , 2015, 9, 450-461.	2.9	8
262	Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1090-1098.	10.7	1,861
263	Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1634-1640.	3.3	2
264	Ten weeks to live: A population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands. <i>Acta Oncologica</i> , 2015, 54, 403-410.	1.8	30
265	A qualitative analysis of experiences of patients with metastatic breast cancer participating in a mindfulness-based intervention. <i>Palliative Medicine</i> , 2015, 29, 182-183.	3.1	6
266	All eyes on the patient: the influence of oncologists' nonverbal communication on breast cancer patients' trust. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 161-171.	2.5	53
267	Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 957-967.	2.3	25
268	Inflammatory breast cancer: An overview. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 116-126.	4.4	113
269	Improved metastasis-free survival in nonadjuvantly treated postmenopausal breast cancer patients with chemokine receptor 5 del32 frameshift mutations. <i>International Journal of Cancer</i> , 2015, 136, 91-97.	5.1	16
270	First-line doublet or triplet chemotherapy for advanced esophagogastric cancer: A systematic review and meta-analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, e15090-e15090.	1.6	0

#	ARTICLE	IF	CITATIONS
271	The prognostic value of a modified tumor regression grade after neoadjuvant chemoradiotherapy and resection of esophageal carcinoma.. Journal of Clinical Oncology, 2015, 33, 4066-4066.	1.6	3
272	The prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and esophagectomy .. Journal of Clinical Oncology, 2015, 33, 4058-4058.	1.6	1
273	How can communication by oncologists enhance patients' trust? An experimental study. Annals of Oncology, 2014, 25, 896-901.	1.2	62
274	Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression. Molecular Pharmaceutics, 2014, 11, 4249-4257.	4.6	8
275	Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Annals of Oncology, 2014, 25, 998-1004.	1.2	33
276	Blocking Hedgehog release from pancreatic cancer cells increases paracrine signaling potency. Journal of Cell Science, 2014, 128, 129-39.	2.0	24
277	To Treat or Not To Treat: Who Should Decide?. Oncologist, 2014, 19, 433-436.	3.7	7
278	Lymph Node Retrieval During Esophagectomy With and Without Neoadjuvant Chemoradiotherapy. Annals of Surgery, 2014, 260, 786-793.	4.2	134
279	Quantification of Patient-Specific Assay Interference in Different Formats of Enzyme-Linked Immunoassays for Therapeutic Monoclonal Antibodies. Therapeutic Drug Monitoring, 2014, 36, 765-770.	2.0	8
280	Comparison of liver SUV using unenhanced CT versus contrast-enhanced CT for attenuation correction in 18F-FDG PET/CT. Nuclear Medicine Communications, 2014, 35, 472-477.	1.1	7
281	The Cancer Worry Scale. Cancer Nursing, 2014, 37, E44-E50.	1.5	170
282	Treatment Related Impairments in Arm and Shoulder in Patients with Breast Cancer: A Systematic Review. PLoS ONE, 2014, 9, e96748.	2.5	210
283	Risk estimations and treatment decisions in early stage breast cancer: Agreement among oncologists and the impact of the 70-gene signature. European Journal of Cancer, 2014, 50, 1045-1054.	2.8	13
284	Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. BMC Cancer, 2014, 14, 56.	2.6	24
285	Dynamics of IGF-1R Expression During Endocrine Breast Cancer Treatment. Molecular Imaging and Biology, 2014, 16, 529-37.	2.6	4
286	Radionuclide imaging of drug delivery for patient selection in targeted therapy. Expert Opinion on Drug Delivery, 2014, 11, 175-185.	5.0	7
287	Preoperative Chemoradiation Therapy in Combination With Panitumumab for Patients With Resectable Esophageal Cancer: The PACT Study. International Journal of Radiation Oncology Biology Physics, 2014, 90, 190-196.	0.8	24
288	Early myocardial deformation abnormalities in breast cancer survivors. Breast Cancer Research and Treatment, 2014, 146, 127-135.	2.5	12

#	ARTICLE	IF	CITATIONS
289	Targeted therapy for advanced esophagogastric adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 68-76.	4.4	22
290	The life in sight application study (LISA): design of a randomized controlled trial to assess the role of an assisted structured reflection on life events and ultimate life goals to improve quality of life of cancer patients. <i>BMC Cancer</i> , 2013, 13, 360.	2.6	14
291	Distress screening remains important during follow-up after primary breast cancer treatment. <i>Supportive Care in Cancer</i> , 2013, 21, 2107-2115.	2.2	71
292	Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. <i>European Radiology</i> , 2013, 23, 748-756.	4.5	65
293	Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients. <i>European Journal of Radiology</i> , 2013, 82, 1416-1422.	2.6	18
294	The strength of small: Improved targeting of Insulin-like Growth Factor-1 Receptor (IGF-1R) with F(ab ϵ) ₂ -R1507 fragments in Ewing sarcomas. <i>European Journal of Cancer</i> , 2013, 49, 2851-2858.	2.8	10
295	Aggressive fibromatosis in the head and neck region: Benign tumor with often mutilating effects. <i>Head and Neck</i> , 2013, 35, E246-50.	2.0	10
296	Screening Patient Spirituality and Spiritual Needs in Oncology Nursing. <i>Holistic Nursing Practice</i> , 2013, 27, 207-216.	0.7	19
297	Arthralgia During Aromatase Inhibitor Treatment in Early Breast Cancer Patients. <i>Cancer Nursing</i> , 2013, 36, 52-59.	1.5	33
298	Bevacizumab reduces tumor targeting of anti-epidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. <i>International Journal of Cancer</i> , 2013, 133, 307-314.	5.1	49
299	Hypoxia Regulation of Phosphokinases and the Prognostic Value of pAKT in Breast Cancer. <i>International Journal of Biological Markers</i> , 2013, 28, 151-160.	1.8	11
300	β -Crystallin Expression is Correlated with Phospho-ERK1/2 Expression in Human Breast Cancer. <i>International Journal of Biological Markers</i> , 2013, 28, 365-370.	1.8	5
301	Magnetic Resonance Spectroscopic Imaging and Volumetric Measurements of the Brain in Patients with Postcancer Fatigue: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2013, 8, e74638.	2.5	7
302	Moyamoya Disease Misdiagnosed As Leptomeningeal Metastases. <i>Journal of Clinical Oncology</i> , 2012, 30, e382-e385.	1.6	6
303	Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with ¹⁸ F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 146-153.	5.0	66
304	Comparison of Attitudes of Guilt and Forgiveness in Cancer Patients Without Evidence of Disease and Advanced Cancer Patients in a Palliative Care Setting. <i>Cancer Nursing</i> , 2012, 35, 483-492.	1.5	9
305	Palliative Care for an Islamic Patient: Changing Frameworks. <i>Journal of Palliative Medicine</i> , 2012, 15, 1053-1055.	1.1	10
306	Axillary Recurrence After a Tumor-Positive Sentinel Lymph Node Biopsy Without Axillary Treatment: A Review of the Literature. <i>Annals of Surgical Oncology</i> , 2012, 19, 4140-4149.	1.5	48

#	ARTICLE	IF	CITATIONS
307	Optimization of IGF-1R SPECT/CT Imaging Using ¹¹¹ In-Labeled F(ab ²) and Fab Fragments of the Monoclonal Antibody R1507. <i>Molecular Pharmaceutics</i> , 2012, 9, 2314-2321.	4.6	35
308	Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome. <i>BMC Immunology</i> , 2012, 13, 71.	2.2	9
309	Physiological and neurophysiological determinants of postcancer fatigue: design of a randomized controlled trial. <i>BMC Cancer</i> , 2012, 12, 256.	2.6	8
310	Tumour response prediction by diffusion-weighted MR imaging: Ready for clinical use?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 194-207.	4.4	61
311	Menopausal status and adjuvant hormonal therapy for breast cancer patients: A practical guideline. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 252-260.	4.4	36
312	Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1858-1867.	6.4	24
313	Letter to the Editor: Interobserver Variability of Heart-to-Mediastinum Ratio in I-123 MIBG Sympathetic Imaging. <i>Current Cardiology Reports</i> , 2012, 14, 389-390.	2.9	3
314	Encouraging results in older patients receiving chemotherapy: A retrospective analysis of treatment guideline adherence in daily practice. <i>Geriatrics and Gerontology International</i> , 2012, 12, 80-85.	1.5	5
315	Tumor hypoxia as a mechanism of resistance to bevacizumab in a murine model. <i>Journal of Clinical Oncology</i> , 2012, 30, e13111-e13111.	1.6	1
316	Breaking the bad news: Experiences of contingency in advanced cancer patients. <i>Journal of Clinical Oncology</i> , 2012, 30, e19560-e19560.	1.6	3
317	Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma. <i>Acta Oncologica</i> , 2011, 50, 462-465.	1.8	14
318	Vascular and Metabolic Response to Bevacizumab-Containing Regimens in Two Patients With Colorectal Liver Metastases Measured by Dynamic Contrast-Enhanced MRI and Dynamic 18F-FDG-PET. <i>Clinical Colorectal Cancer</i> , 2011, 10, E1-E5.	2.3	16
319	Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients. <i>European Journal of Radiology</i> , 2011, 80, 655-661.	2.6	6
320	Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. <i>Breast Cancer Research</i> , 2011, 13, R82.	5.0	74
321	Constitutive expression of γ -H2AX has prognostic relevance in triple negative breast cancer. <i>Radiotherapy and Oncology</i> , 2011, 101, 39-45.	0.6	74
322	Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. <i>Cancer Imaging</i> , 2011, 11, 259-265.	2.8	37
323	Coping, Quality of Life, Depression, and Hopelessness in Cancer Patients in a Curative and Palliative, End-of-Life Care Setting. <i>Cancer Nursing</i> , 2011, 34, 302-314.	1.5	51
324	Time Perception of Cancer Patients Without Evidence of Disease and Advanced Cancer Patients in a Palliative, End-of-Life-Care Setting. <i>Cancer Nursing</i> , 2011, 34, 453-463.	1.5	23

#	ARTICLE	IF	CITATIONS
325	Perspectives on Death and an Afterlife in Relation to Quality of Life, Depression, and Hopelessness in Cancer Patients Without Evidence of Disease and Advanced Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2011, 41, 1048-1059.	1.2	14
326	Scintigraphic Techniques for Early Detection of Cancer Treatmentâ€“Induced Cardiotoxicity. <i>Journal of Nuclear Medicine</i> , 2011, 52, 560-571.	5.0	92
327	Group medical visits in the follow-up of women with a BRCA mutation: design of a randomized controlled trial. <i>BMC Women's Health</i> , 2011, 11, 39.	2.0	14
328	Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer. <i>Cancer</i> , 2011, 117, 3670-3681.	4.1	57
329	When Hope Is All There Is Left. <i>Oncologist</i> , 2011, 16, 914-916.	3.7	5
330	Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507. <i>Clinical Cancer Research</i> , 2011, 17, 7693-7703.	7.0	39
331	Images of God in Relation to Coping Strategies of Palliative Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2010, 40, 495-501.	1.2	30
332	Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041). <i>Clinical Cancer Research</i> , 2010, 16, 1315-1323.	7.0	39
333	ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1565-1572.	5.0	84
334	Spiritual Care in Patients With Advanced Cancer: What Does It Imply?. <i>Journal of Clinical Oncology</i> , 2010, 28, e332-e332.	1.6	2
335	Tripleâ€“negative breast cancer: Present challenges and new perspectives. <i>Molecular Oncology</i> , 2010, 4, 209-229.	4.6	252
336	Religious Coping and Life-Prolonging Care. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 257.	7.4	2
337	Dying at the Right Time: A Modern Dilemma. <i>Oncologist</i> , 2009, 14, 642-643.	3.7	3
338	Chemotherapy Response Monitoring of Colorectal Liver Metastases by Dynamic Gd-DTPAâ€“Enhanced MRI Perfusion Parameters and 18F-FDG PET Metabolic Rate. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1777-1784.	5.0	29
339	Feasibility of concurrent dual contrast enhancement using CEST contrast agents and superparamagnetic iron oxide particles. <i>Magnetic Resonance in Medicine</i> , 2009, 61, 970-974.	3.0	33
340	Ischemic neuropathy and rhabdomyolysis as presenting symptoms of postpartum cardiomyopathy. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 458-460.	2.1	0
341	Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy. <i>Cancer Treatment Reviews</i> , 2009, 35, 309-321.	7.7	151
342	Magnetovaccination as a Novel Method to Assess and Quantify Dendritic Cell Tumor Antigen Capture and Delivery to Lymph Nodes. <i>Cancer Research</i> , 2009, 69, 3180-3187.	0.9	83

#	ARTICLE	IF	CITATIONS
343	Monitoring and Predicting Response to Therapy with ¹⁸ F-FDG PET in Colorectal Cancer: A Systematic Review. <i>Journal of Nuclear Medicine</i> , 2009, 50, 43S-54S.	5.0	197
344	Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. <i>Annals of Oncology</i> , 2008, 19, 348-352.	1.2	98
345	Artificial reporter gene providing MRI contrast based on proton exchange. <i>Nature Biotechnology</i> , 2007, 25, 217-219.	17.5	379
346	Carbogen Breathing Differentially Enhances Blood Plasma Volume and 5-Fluorouracil Uptake in Two Murine Colon Tumor Models with a Distinct Vascular Structure. <i>Neoplasia</i> , 2006, 8, 477-487.	5.3	17
347	Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 473-482.	0.8	68
348	Assessment of absolute blood volume in carcinoma by USPIO contrast-enhanced MRI. <i>Magnetic Resonance Imaging</i> , 2006, 24, 279-286.	1.8	25
349	Monitoring fluoropyrimidine metabolism in solid tumors with in vivo ¹⁹ F magnetic resonance spectroscopy. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 321-343.	4.4	34
350	Gadopentetate Dimeglumine and FDG Uptake in Liver Metastases of Colorectal Carcinoma as Determined with MR Imaging and PET. <i>Radiology</i> , 2005, 237, 181-188.	7.3	20
351	Pitfall in HPLC Assay for Urinary Metanephrines: An Unusual Type of Interference Caused by Methenamine Intake. <i>Clinical Chemistry</i> , 2004, 50, 1097-1099.	3.2	13
352	Effects of nicotinamide and carbogen in different murine colon carcinomas: Immunohistochemical analysis of vascular architecture and microenvironmental parameters. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 310-321.	0.8	30
353	Systemic treatment of advanced colorectal carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 283-289.	1.6	13
354	Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases. <i>Journal of Magnetic Resonance Imaging</i> , 2003, 18, 315-320.	3.4	45
355	Optimization of localized ¹⁹ F magnetic resonance spectroscopy for the detection of fluorinated drugs in the human liver. <i>Magnetic Resonance in Medicine</i> , 2003, 50, 303-308.	3.0	38
356	Guillain-Barré syndrome as presenting feature in a patient with lupus nephritis, with complete resolution after cyclophosphamide treatment. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 840-842.	0.7	18